12-month data set up Pfizer DMD gene therapy for Phase III, but SAEs may give Sarepta safety edge

Pfizer believes encouraging long-term efficacy data and recently installed protocols for mitigating adverse events will help the pharma advance its DMD gene therapy into Phase III testing within the next few months as it ramps up its manufacturing capabilities. But another SAE for the program appears to signal that a Sarepta-Roche gene therapy also slated to enter Phase III this year still has an advantage on safety.

The updated Phase Ib data from Pfizer Inc. (NYSE:PFE) for PF-06939926 included three additional patients in the high-dose cohort and efficacy data out to 12 months...